Patient Characteristics Before Injection with 111In-ABY-025
| Patient no. | Age (y) | HER2 status in primary tumor (HercepTest) | Primary tumor ER/PgR | Pretreatment serum HER2 (μg/L) | Metastasis locations on 18F-FDG PET/CT | Injected 111In-ABY-025 (MBq) | On trastuzumab during imaging | Therapy history* |
| 1 | 69 | 3+ | −/− | 21 | Lymph node | 131 | Yes | S, R, C, T, L |
| 2 | 57 | 3+ | +/− | 26 | Lymph node, liver, bone | 135 | Yes | S, R, C, E, T, L |
| 3 | 46 | 3+ | −/− | 56 | Lymph node, bone, liver, adrenal | 139 | Yes | S, R, C, T, L |
| 4 | 70 | 3+ | +/− | 8.8 | Lymph node, lung, bone, brain, thyroid | 153 | Yes | S, R, C, E, T, L |
| 5 | 66 | 1+ | −/− | 16 | Lymph node, bone | 137 | No | S, R, C, |
| 6 | 65 | 0 | +/− | 12 | Bone, liver, lung | 139 | No | S, R, C, E |
| 7 | 57 | 3+ | +/+ | 23 | Lymph node, bone | 154 | Yes | S, C, E, T, L |
↵* More information on therapy history is provided in the supplemental material.
ER = estrogen receptor; PgR = progesterone receptor; S = surgery; R = radiotherapy; C = chemotherapy; E = endocrine therapy; T = trastuzumab; L = lapatinib.